Essex Bio-Technology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC

Reuters

Jul 23

<a href="https://laohu8.com/S/01061">Essex Bio-Tech</a>nology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC

Essex Bio-Technology Limited has announced that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration for the registration and commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China. This approval allows Essex Bio-Technology to provide additional treatment options for patients suffering from dry eye syndromes, including conjunctival epithelium injury and tear abnormalities, in the PRC. This new product complements the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops, enhancing the company's offering in the ophthalmic treatment market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief on July 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553524892"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553524892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553524892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553524892","market":"us","top_or_hot":-1,"title":"Essex Bio-Technology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01061\">Essex Bio-Tech</a>nology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Essex Bio-Technology Limited has announced that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration for the registration and commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China. This approval allows Essex Bio-Technology to provide additional treatment options for patients suffering from dry eye syndromes, including conjunctival epithelium injury and tear abnormalities, in the PRC. This new product complements the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops, enhancing the company's offering in the ophthalmic treatment market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Technology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Technology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-23 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01061\">Essex Bio-Tech</a>nology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Essex Bio-Technology Limited has announced that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration for the registration and commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China. This approval allows Essex Bio-Technology to provide additional treatment options for patients suffering from dry eye syndromes, including conjunctival epithelium injury and tear abnormalities, in the PRC. This new product complements the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops, enhancing the company's offering in the ophthalmic treatment market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL21WZPB:1","article_id":"2553524892","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553524892","pubTimestamp":1753274365,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Essex Bio-Technology Limited has announced that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration for the registration and commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China. This approval allows Essex Bio-Technology to provide additional treatment options for patients suffering from dry eye syndromes, including conjunctival epithelium injury and tear abnormalities, in the PRC. This new product complements the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops, enhancing the company's offering in the ophthalmic treatment market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技","BK1161":"生物科技"},"translate_title":"亿胜生物科技有限公司获批在中国商业化多剂量地夸磷醇钠滴眼液","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":0.9},"content_text":"Essex Bio-Technology Limited Secures Approval to Commercialise Multi-Dose Diquafosol Sodium Eye Drops in the PRC\n    \n\n        Essex Bio-Technology Limited has announced that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration for the registration and commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China. This approval allows Essex Bio-Technology to provide additional treatment options for patients suffering from dry eye syndromes, including conjunctival epithelium injury and tear abnormalities, in the PRC. This new product complements the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops, enhancing the company's offering in the ophthalmic treatment market.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Essex Bio-Technology Limited published the original content used to generate this news brief on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}